Overview
No overview information available.
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Research Report
Comprehensive Report on LY-3537031: An Investigational Dual GIPR/GLP-1R Agonist
1. Executive Summary of LY-3537031
LY-3537031 is an investigational synthetic peptide currently under development by Eli Lilly and Company, positioned within the therapeutic area of endocrinology and metabolic diseases, with a primary focus on obesity.[1] The compound functions as a dual agonist for the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R).[1] This mechanism of action is well-established within Eli Lilly's portfolio, notably with the successful drug tirzepatide. LY-3537031 is administered subcutaneously and is recognized as a New Molecular Entity (NME), a designation that underscores its novelty and potential for market exclusivity upon approval.[2]
The clinical development program for LY-3537031 is in Phase 1. A single ascending dose (SAD) study, NCT04648865, conducted in healthy Japanese volunteers, has been completed.[1] A more extensive multiple ascending dose (MAD) study, NCT06606106, is currently recruiting participants, including overweight and obese individuals, as well as healthy volunteers from diverse ethnic backgrounds, including Japanese and Chinese cohorts.[1] This ongoing trial aims to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of LY-3537031, including its effects on body weight and gastric emptying. The development of LY-3537031, identified in Eli Lilly's pipeline as "GIP/GLP-1 Coagonist III" [6], signifies a continued strategic investment by the company in leveraging dual incretin agonism to address the significant unmet medical needs in obesity and related metabolic conditions.
2. Introduction to LY-3537031
Background and Rationale for Development in Obesity and Metabolic Diseases
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2024/09/20 | Phase 1 | Recruiting | |||
2020/12/02 | Phase 1 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
No FDA approvals found for this drug. |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
No TGA approvals found for this drug. |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
---|---|---|---|---|---|
No Health Canada approvals found for this drug. |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
---|---|---|---|---|---|
No CIMA AEMPS (Spain) approvals found for this drug. |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Philippines FDA approvals found for this drug. |
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Saudi SFDA approvals found for this drug. |
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Malaysia NPRA approvals found for this drug. |
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
---|---|---|---|---|---|
No UK EMC drug information found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.